Clinical trials: Ovarian Neoplasms, open to volunteers
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the…
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT01174121
- Testing
- Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Sex-cord Stromal Tumor, Testicular Stromal Tumors
International Ovarian & Testicular Stromal Tumor Registry
Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood, have recently been found to be associated with a…
- Conditions
- Ovarian Sex-cord Stromal Tumor, Testicular Stromal Tumors, Ovarian Small Cell Carcinoma
- Trial name
- OTST (NCT01970696)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Ovarian Cancer, Fallopian Tube Cancer
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
- Trial name
- N-Plus (NCT05460000)
- Testing
- 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 640 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Low-Grade Serous Ovarian Cancer
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC).
- Trial name
- CHAMELEON (NCT06394804)
- Testing
- Avutometinib, Defactinib, Letrozole
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer, Gynecologic Cancer
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy (RT) to at least one metastatic lesion during routine care.
- Conditions
- Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer
- Trial name
- OLIGYNE-10 RT (NCT07883798)
- Testing
- Routine-care metastasis-directed radiotherapy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Platinum-resistant Ovarian Cancer
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.
- Trial name
- NCT07489287
- Testing
- GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Cancer
Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors
This randomized controlled study will evaluate the effects of web-based ovarian cancer awareness education on women's awareness of ovarian cancer, health beliefs, and risk-reducing behaviors.
- Trial name
- NCT07882485
- Testing
- Web-Based Ovarian Cancer Awareness Education, General Reproductive Health Information
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Ege University
High Grade Serous Ovarian Cancer, Folate Receptor Alpha Positive
Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
This is a single-country, retrospective, observational biomarker study conducted in Greece to evaluate Folate Receptor Alpha (FRα) expression in patients with high-grade serous ovarian, fallopian tube, and primary peritoneal…
- Trial name
- FRONTIER (NCT07889843)
- Where
- Greece
- Volunteers
- 200 people
- Sponsor
- Hellenic Cooperative Oncology Group
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma
- Trial name
- NCT05950464
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer Recurrent
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly.
- Trial name
- NCT06843447
- Testing
- Raludotatug Deruxtecan, Carboplatin, Paclitaxel
- Where
- 39 sites in United States, Canada and 6 more
- Volunteers
- 605 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer, Ovarian Neoplasms
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07776691
- Testing
- R-DXd, Bevacizumab
- Where
- 7 sites in United States, Israel and 2 more
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors.
- Trial name
- NCT07778498
- Testing
- TJ102
- Where
- 9 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Phrontline Biopharma
Refractory Malignant Solid Neoplasm, Osteosarcoma
AOH1996 for the Treatment of Refractory Solid Tumors
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory).
- Conditions
- Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas
- Trial name
- NCT05227326
- Testing
- PCNA Inhibitor AOH1996
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- City of Hope Medical Center
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
- Trial name
- NCT06890338
- Testing
- Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
- Where
- 73 sites in United States
- Volunteers
- 140 people
- Sponsor
- AbbVie
Advanced Solid Tumors
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known…
- Trial name
- NCT07360314
- Testing
- M7437
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 138 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Ovarian Cancer, Ovarian Tumor
AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
The goal of this observational study is to learn if a computer program can tell what type of ovarian tumour a person has from a CT scan taken before surgery. The program uses artificial intelligence (AI).
- Conditions
- Ovarian Cancer, Ovarian Tumor, Borderline Ovarian Tumor
- Trial name
- OvaClass (NCT07883551)
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Ovarian Cancer
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study.
- Trial name
- MIROC-1 (NCT03854110)
- Testing
- misetionamide (also known as GP-2250)
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Persevere Therapeutics Inc.